[{"orgOrder":0,"company":"Radiance Biopharma","sponsor":"Biocytogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Licensing Agreement","leadProduct":"YH012","moa":"Erbb2 tyrosine kinase receptor (HER2)","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiance Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiance Biopharma \/ Radiance Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Radiance Biopharma \/ Radiance Biopharma"},{"orgOrder":0,"company":"Radiance Biopharma","sponsor":"Megalith Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"RB-164","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Radiance Biopharma","amount2":1.1699999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1699999999999999,"dosageForm":"Infusion","sponsorNew":"Radiance Biopharma \/ Radiance Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Radiance Biopharma \/ Radiance Biopharma"},{"orgOrder":0,"company":"Radiance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"RB-164","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Radiance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Radiance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Radiance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"RB-164","moa":"ROR1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Radiance Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Radiance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Radiance Biopharma","sponsor":"Novatim Immune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"RB-601","moa":"EGFR\/c-MET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Radiance Biopharma","amount2":1.1699999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.1699999999999999,"dosageForm":"Undisclosed","sponsorNew":"Radiance Biopharma \/ Radiance Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Radiance Biopharma \/ Radiance Biopharma"}]